Clinical Trial

Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines. The aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-13; most recent amendment 2024-09-19.
Trial Details
NCT Number NCT06464380
Lead Sponsor Ain Shams University
Collaborators: Mohamed, Ahmed A., M.D., Amr Amin College of Medicine, University of Sharjah, Sharjah 27272, UAE., Ahmed Cordie Endemic Medicine department, Cairo University Hospitals., Nouran Mohamed Endemic Medicine department, Cairo University Hospitals., Misr University for Science and Technology
Conditions Hepatocellular Carcinoma
Enrollment 40 participants
Start Date 2024-10-30
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-23